Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

22.22
+1.044.91%
Pre-market: 22.330.1100+0.50%06:51 EDT
Volume:579.85K
Turnover:12.80M
Market Cap:681.42M
PE:-4.34
High:22.52
Open:21.05
Low:21.05
Close:21.18
Loading ...

BRIEF-Anaptys Announces Phase 2B Trial Of ANB032, A BTLA Agonist, Did Not Meet Endpoints

Reuters
·
11 Dec 2024

AnaptysBio abandons eczema drug development after mid-stage trial failure

Reuters
·
11 Dec 2024

AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint

TIPRANKS
·
11 Dec 2024

AnaptysBio Inc - Year-End 2024 Cash About $415 Mln

THOMSON REUTERS
·
11 Dec 2024

AnaptysBio Inc - Anb032 Ad Trial and All Further Investment Will Be Discontinued

THOMSON REUTERS
·
11 Dec 2024

AnaptysBio Inc - Anb032 Well Tolerated With No Safety Signals Observed

THOMSON REUTERS
·
11 Dec 2024

Anaptys Announces Phase 2B Trial of Anb032, a Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

THOMSON REUTERS
·
11 Dec 2024

AnaptysBio Inc: Anticipate Top-Line Phase 2B Data in Rheumatoid Arthritis in February 2025

THOMSON REUTERS
·
11 Dec 2024

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

GlobeNewswire
·
11 Dec 2024

AnaptysBio (ANAB) was downgraded to a Hold Rating at BTIG

TIPRANKS
·
10 Dec 2024

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)

TIPRANKS
·
06 Dec 2024

AnaptysBio Cut to Neutral From Buy by BTIG

Dow Jones
·
02 Dec 2024

AnaptysBio Shares Down 6.4% After Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
02 Dec 2024

BTIG Downgrades AnaptysBio to Neutral From Buy

MT Newswires Live
·
02 Dec 2024

AnaptysBio Shares Down 3.85% Premarket After Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
02 Dec 2024

AnaptysBio Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
02 Dec 2024

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks
·
25 Nov 2024

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Simply Wall St.
·
16 Nov 2024

TD Cowen Reaffirms Their Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
15 Nov 2024

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)

TIPRANKS
·
11 Nov 2024